Device Studies
Active Studies
ARCHWAY (Roche/Genentech)
A phase 3, multicenter, randomized, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.
PORTAL (Roche/Genentech)
A multicenter, open-label extension study to evaluate the long-term safety and tolerabilty of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.
Completed Studies
CLEAR (DigiSight)
A 3 month, phase 1 and 2 studies on THE CORRELATION OF PAXOS CHECKUP MOBILE APP TO STANDARD IN OFFICE VISUAL ASSESSMENT.
LADDER (Genentech)
A 20 month, phase 2, multicenter, randomized, active treatment-controlled study of the efficacy and safety of the ranibizumab port delivery system for sustained delivery of ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
